logo

ALXO

ALX Oncology·NASDAQ
--
--(--)
--
--(--)
5.75 / 10
Netural

ALXO's fundamental score of 5.8/10 indicates modest strength. Key positives include a favorable PB-ROE (0.1220) and Asset-MV (-0.5007) ranking in higher-performance quartiles, while Revenue-MV (-0.2574) and Net profit/Total profit (100%) show caution. Overall, the fundamentals warrant a guarded bullish view.

Fundamental(5.75)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.26
Score1/3
Weight9.19%
1M Return5.20%
Inventory turnover ratio
Value47.85
Score3/3
Weight8.07%
1M Return5.26%
Gross profit margin (%)
Value36.70
Score1/3
Weight-0.71%
1M Return-0.54%
Profit-MV
Value0.46
Score2/3
Weight13.76%
1M Return7.79%
PB-ROE
Value0.12
Score3/3
Weight21.61%
1M Return11.47%
Current assets turnover ratio
Value1.78
Score2/3
Weight1.61%
1M Return1.15%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.17%
1M Return0.86%
Asset-MV
Value-0.50
Score3/3
Weight31.93%
1M Return14.99%
Cash-MV
Value-0.07
Score2/3
Weight13.78%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.41%
1M Return-0.30%
Is ALXO undervalued or overvalued?
  • ALXO scores 5.75/10 on fundamentals and holds a Fair valuation at present. Backed by its -99.54% ROE, 0.00% net margin, -2.49 P/E ratio, 6.00 P/B ratio, and 32.32% earnings growth, these metrics solidify its Netural investment rating.